Bluebird Bio

Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease
Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease
CP Wire
Bluebird Bio
sickle cell disease
LentiGlobin
gene therapy
Flag link:
Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder
Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder
CP Wire
Bluebird Bio
gene therapy
LentiGlobin
beta thalassemia
sickle cell disease
Flag link:
Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease
Bluebird Bio
sickle cell disease
LentiGlobin
Flag link:
Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder
Bluebird Bio
β-thalassemia
sickle cell disease
LentiGlobin
Flag link:
ASCO18: Who were the big winners and losers?
ASCO18: Who were the big winners and losers?
Biopharma Dive
ASCO 2018
Merck
Loxo Oncology
Bluebird Bio
Celgene
Roche
Nektar
Flag link:
#ASCO18: A Weekend of Surprises
#ASCO18: A Weekend of Surprises
Motley Fool
ASCO 2018
Bluebird Bio
Loxo Oncology
Nektar Therapeutics
Celgene
Grail
Flag link:
Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are Not A Cure Yet
Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are Not A Cure Yet
Forbes
Bluebird Bio
CAR-T
Multiple Myeloma
bb2121
ASCO 2018
Flag link:
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
Flag link:
Bluebird widens hunt for TCR therapies in revised Medigene deal
Bluebird widens hunt for TCR therapies in revised Medigene deal
Biopharma Dive
Bluebird Bio
Medigene
CAR-T
Flag link:
bluebird bio Looks for Data Ahead
bluebird bio Looks for Data Ahead
Motley Fool
Bluebird Bio
earnings
Flag link:
2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
Motley Fool
Celgene
Bluebird Bio
beta thalassemia
LentiGlobin
luspatercept
Flag link:
Is bluebird bio One Step Closer to Its First Commercial Drug?
Is bluebird bio One Step Closer to Its First Commercial Drug?
Motley Fool
Bluebird Bio
beta thalassemia
LentiGlobin
Flag link:
Bluebird’s gene therapy for beta-thalassemia falls short of a cure, but still wows in 22 patients
Bluebird’s gene therapy for beta-thalassemia falls short of a cure, but still wows in 22 patients
Endpoints
Bluebird Bio
beta-thalassemia
gene therapy
Flag link:
Celgene, bluebird revise deal to co-develop CAR-T therapy
Celgene, bluebird revise deal to co-develop CAR-T therapy
Biopharma Dive
Celgene
Bluebird Bio
drug development
CAR-T
bb2121
Multiple Myeloma
Flag link:
bluebird bio Updates Plans for the Year Ahead
bluebird bio Updates Plans for the Year Ahead
Motley Fool
Bluebird Bio
earnings
Flag link:
How Celgene Hopes to Cash In on CAR-T
How Celgene Hopes to Cash In on CAR-T
Yahoo/Motley Fool
Celgene
CAR-T
JCAR017
bb2121
Bluebird Bio
Flag link:
As CAR-Ts go from candidates to brands, what's the marketing strategy?
As CAR-Ts go from candidates to brands, what's the marketing strategy?
Medical Marketing and Media
CAR-T
drug marketing
JCAR017
Juno Therapeutics
Celgene
bb2121
Bluebird Bio
apalutamide
Janssen
Flag link:
2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs
2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs
TheStreet.com
biotech
M&A
Bluebird Bio
Amicus Therapeutics
Flag link:
3 Small Biotechs That Big Drugmakers Are Probably Drooling Over
3 Small Biotechs That Big Drugmakers Are Probably Drooling Over
Motley Fool
biotech
Bluebird Bio
Madrigal Pharmaceuticals
SAGE Therapeutics
Flag link:
Bluebird Bio Shouldn’t Be Blue About Celgene’s Juno Deal
Bluebird Bio Shouldn’t Be Blue About Celgene’s Juno Deal
Washington Post, DC
Bluebird Bio
Celgene
Juno Therapeutics
M&A
CAR-T
Flag link:

Pages